Nasdaq Bmrn News Today

Motley Fool Wealth Management LLC trimmed its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 3.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 470,289 shares of the biotechnology company’s stock after selling 18,667 shares during the period. BioMarin Pharmaceutical makes up about 2.4% of Motley Fool Wealth […]

Motley Fool Wealth Management LLC reduced its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 3.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 470,289 shares of the biotechnology company’s stock after selling 18,667 shares during the quarter. […]

BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its price objective decreased by Morgan Stanley from $115.00 to $112.00 in a research note released on Friday, Benzinga reports. Morgan Stanley currently has an overweight rating on the biotechnology company’s stock. Several other equities research analysts have also recently weighed in on the company. Cantor Fitzgerald reaffirmed […]

Xponance Inc. cut its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 2.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,966 shares of the biotechnology company’s stock after selling 203 shares during the quarter. Xponance […]

BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its target price lowered by Citigroup from $94.00 to $91.00 in a research note published on Thursday morning, Benzinga reports. Citigroup currently has a neutral rating on the biotechnology company’s stock. Several other research analysts have also issued reports on BMRN. Royal Bank of Canada restated a sector […]

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) had its target price decreased by research analysts at Morgan Stanley from $115.00 to $112.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. Morgan Stanley’s price target indicates a potential upside of 37.34% […]

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) updated its FY24 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $2.75-2.95 for the period, compared to the consensus estimate of $2.59. The company issued revenue guidance of $2.7-2.8 billion, compared to the consensus revenue estimate of $2.75 billion. BioMarin Pharmaceutical also updated […]

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report)‘s stock had its “overweight” rating reiterated by analysts at Cantor Fitzgerald in a report issued on Thursday, Benzinga reports. They currently have a $110.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price target would indicate a potential upside of 34.47% from the stock’s previous close. Several […]

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) had its price objective boosted by analysts at Wells Fargo & Company from $100.00 to $110.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price target would […]

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 2.750-2.950 for the period, compared to the consensus earnings per share estimate of 1.650. The company issued revenue guidance of $2.7 billion-$2.8 billion, compared to the consensus revenue […]